Terbinafine-induced subacute cutaneous lupus erythematosus.
Oral terbinafine is licensed for use in onychomycosis after positive confirmation of infection. We describe five cases of subacute cutaneous lupus erythematosus associated with terbinafine therapy. All cases had positive antibodies to extractable nuclear antigens, predominantly anti-Ro, and several had a history of pre-existing autoimmune disease. Terbinafine should only be prescribed after confirmation of infection by microscopy or culture.
McKay
David A
DA
Department of Dermatology, Royal Infirmary of Edinburgh, Edinburgh, UK. david.mckay@ed.ac.uk
Schofield
Olivia M V
OM
Benton
E Claire
EC
D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D000935:Antifungal Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced*; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects*; D014009:Onychomycosis / Q000188:drug therapy; D000077291:Terbinafine
D000974:Antibodies, Antinuclear; D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine